What is Insight Molecular Diagnostics Inc.'s earnings per share (EPS)?

Insight Molecular Diagnostics Inc. (IMDX) reported diluted earnings per share of $-1.65 for fiscal year 2025. This represents a 64.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Insight Molecular Diagnostics Inc. Financials

IMDX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Insight Molecular Diagnostics Inc. (IMDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMDX FY2025 2026-05-13

Commercial revenue is rising, but the business still runs on external financing because product gross profit remains far below operating spend.

From FY2023 to FY2025, revenue nearly tripled to $4.1M while gross margin reached 56.7%. But FY2025 gross profit of $2.3M was still dwarfed by $26.5M of R&D plus SG&A, so better unit economics have not yet changed the company’s funding model.

The balance sheet has shifted from cushion to dependence: cash was $11.6M against current liabilities of $12.1M, leaving little room for burn to be covered from cash alone. Negative equity means liabilities now exceed assets, so the business is being carried more by fresh funding than by accumulated capital.

Free cash flow worsened to -$25.4M even though operating cash flow was -$22.2M, and that gap points to higher reinvestment rather than only day-to-day losses. The main driver was capital spending of $3.2M after $516K the year before, suggesting the company is still building capability while it is not yet self-funding.

Financial Health Signals

Financial Health Score 47/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Insight Molecular Diagnostics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-26.39

Insight Molecular Diagnostics Inc. scores -26.39, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($156.3M) relative to total liabilities ($57.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Insight Molecular Diagnostics Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

441.72x

For every $1 of reported earnings, Insight Molecular Diagnostics Inc. generates $441.72 in operating cash flow (-$22.2M OCF vs -$50K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-469.0x

Insight Molecular Diagnostics Inc. earns $-469.0 in operating income for every $1 of interest expense (-$51.1M vs $109K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.1M

YoY+115.6%

5Y CAGR+27.2%

Insight Molecular Diagnostics Inc. generated $4.1M in revenue in fiscal year 2025. This represents an increase of 115.6% from the prior year.

EBITDA

-$48.9M

YoY+17.7%

Insight Molecular Diagnostics Inc.'s EBITDA was -$48.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17.7% from the prior year.

Net Income

-$50K

YoY+17.2%

Insight Molecular Diagnostics Inc. reported -$50K in net income in fiscal year 2025. This represents an increase of 17.2% from the prior year.

EPS (Diluted)

$-1.65

YoY+64.6%

Insight Molecular Diagnostics Inc. earned $-1.65 per diluted share (EPS) in fiscal year 2025. This represents an increase of 64.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$25.4M

YoY-19.6%

Insight Molecular Diagnostics Inc. generated -$25.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 19.6% from the prior year.

Cash & Debt

$11.6M

YoY+34.1%

5Y CAGR+10.2%

10Y CAGR+46.3%

Insight Molecular Diagnostics Inc. held $11.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

29M

YoY+64.3%

Insight Molecular Diagnostics Inc. had 29M shares outstanding in fiscal year 2025. This represents an increase of 64.3% from the prior year.

Margins & Returns

Gross Margin

56.7%

YoY+17.3pp

5Y CAGR+109.2pp

Insight Molecular Diagnostics Inc.'s gross margin was 56.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 17.3 percentage points from the prior year.

Operating Margin

-1260.8%

YoY+1984.4pp

5Y CAGR+1182.6pp

Insight Molecular Diagnostics Inc.'s operating margin was -1260.8% in fiscal year 2025, reflecting core business profitability. This is up 1984.4 percentage points from the prior year.

Net Margin

-1.2%

YoY+2.0pp

5Y CAGR+2460.3pp

Insight Molecular Diagnostics Inc.'s net profit margin was -1.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.0 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$15.9M

YoY+61.6%

5Y CAGR+10.2%

10Y CAGR+14.9%

Insight Molecular Diagnostics Inc. invested $15.9M in research and development in fiscal year 2025. This represents an increase of 61.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$3.2M

YoY+517.2%

5Y CAGR+21.0%

10Y CAGR+79.8%

Insight Molecular Diagnostics Inc. invested $3.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 517.2% from the prior year.

IMDX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.1M+115.6%	$1.9M+25.1%	$1.5M+56.9%	$958K-56.4%	$2.2M+80.8%	$1.2M
Cost of Revenue	$1.8M+66.2%	$1.1M+5.1%	$1.0M+13.9%	$880K+26.3%	$697K-62.4%	$1.9M
Gross Profit	$2.3M+210.5%	$740K+79.2%	$413K+429.5%	$78K-94.5%	$1.4M+322.2%	-$639K
R&D Expenses	$15.9M+61.6%	$9.8M+5.9%	$9.3M+27.3%	$7.3M+45.0%	$5.0M-48.6%	$9.8M
SG&A Expenses	$10.6M+4.2%	$10.2M-8.7%	$11.2M-48.9%	$21.9M-1.8%	$22.3M+32.8%	$16.8M
Operating Income	-$51.1M+16.2%	-$61.0M-142.8%	-$25.1M-39.7%	-$18.0M+66.5%	-$53.7M-80.8%	-$29.7M
Interest Expense	-$109K-29.8%	-$84K-61.5%	-$52K+37.3%	-$83K+60.3%	-$209K+17.1%	-$252K
Income Tax	$0	$0	$0	N/A	-$9.3M-638.5%	-$1.3M
Net Income	-$50K+17.2%	-$61K-118.4%	-$28K+100.0%	-$72.9M-13.7%	-$64.1M-114.1%	-$29.9M
EPS (Diluted)	$-1.65+64.6%	$-4.66-24.3%	$-3.75+71.7%	$-13.25	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$32K-97.2%	$1.1M+338.1%	$260K-49.8%	$518K-75.8%	$2.1M+43.9%	$1.5M+1192.2%	$115K+10.6%	$104K
Cost of Revenue	$17K-97.4%	$648K+435.5%	$121K-28.0%	$168K-79.3%	$813K-6.4%	$869K+1920.9%	$43K+34.4%	$32K
Gross Profit	$15K-96.9%	$484K+248.2%	$139K-60.3%	$350K-73.6%	$1.3M+122.7%	$595K+1090.0%	$50K0.0%	$50K
R&D Expenses	$5.0M-14.9%	$5.8M+50.0%	$3.9M+18.2%	$3.3M+12.2%	$2.9M+29.6%	$2.3M-19.9%	$2.8M+14.8%	$2.5M
SG&A Expenses	$3.0M+28.6%	$2.3M-8.6%	$2.5M-3.9%	$2.6M-15.0%	$3.1M+21.7%	$2.6M-0.2%	$2.6M+6.6%	$2.4M
Operating Income	-$4.4M+81.2%	-$23.4M-112.1%	-$11.0M-12.3%	-$9.8M-44.8%	-$6.8M+79.8%	-$33.6M-148.8%	-$13.5M-191.8%	-$4.6M
Interest Expense	-$23K+11.5%	-$26K+10.3%	-$29K-16.0%	-$25K+13.8%	-$29K+3.3%	-$30K+3.2%	-$31K-287.5%	-$8K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$4.3M-115.8%	$27.2M+350.8%	-$10.9M-11.4%	-$9.7M-46.0%	-$6.7M-124.6%	$27.1M+300.8%	-$13.5M-197.9%	-$4.5M
EPS (Diluted)	$-0.12	N/A	$-0.34-13.3%	$-0.30-15.4%	$-0.26	N/A	$-0.98-172.2%	$-0.36

IMDX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$25.8M-26.6%	$35.1M-53.2%	$74.9M-25.2%	$100.1M-37.3%	$159.6M+187.9%	$55.4M
Current Assets	$15.3M+30.2%	$11.8M+9.9%	$10.7M-58.1%	$25.5M-34.8%	$39.1M+324.3%	$9.2M
Cash & Equivalents	$11.6M+34.1%	$8.6M-8.4%	$9.4M-52.8%	$20.0M-39.3%	$32.9M+361.3%	$7.1M
Inventory	$446K+8.8%	$410K	N/A	N/A	N/A	N/A
Accounts Receivable	$1.1M-30.1%	$1.6M+233.3%	$484K-75.9%	$2.0M+40.0%	$1.4M+607.9%	$203K
Goodwill	N/A	N/A	N/A	N/A	$18.7M+103.4%	$9.2M
Total Liabilities	$57.2M+20.8%	$47.4M-3.9%	$49.3M-18.5%	$60.5M-35.9%	$94.3M+330.1%	$21.9M
Current Liabilities	$12.1M+66.0%	$7.3M+1.1%	$7.2M-40.6%	$12.1M-14.3%	$14.1M+57.0%	$9.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$31.5M-156.3%	-$12.3M-160.0%	$20.5M-40.3%	$34.3M-47.4%	$65.2M+94.8%	$33.5M
Retained Earnings	-$400.8M-14.3%	-$350.5M-20.9%	-$289.9M-11.2%	-$260.7M-38.8%	-$187.8M-51.8%	-$123.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$40.4M+57.0%	$25.8M-41.4%	$43.9M-13.0%	$50.5M-16.3%	$60.4M+72.1%	$35.1M-50.0%	$70.2M-6.0%	$74.7M
Current Assets	$30.5M+99.4%	$15.3M-28.4%	$21.4M-20.3%	$26.8M-26.0%	$36.3M+208.4%	$11.8M+145.3%	$4.8M-51.9%	$10.0M
Cash & Equivalents	$28.2M+143.5%	$11.6M-38.0%	$18.7M-23.0%	$24.3M-21.7%	$31.0M+259.3%	$8.6M+156.8%	$3.4M-63.7%	$9.3M
Inventory	$382K-14.3%	$446K-5.3%	$471K-32.0%	$693K+51.0%	$459K+12.0%	$410K+76.7%	$232K	N/A
Accounts Receivable	$157K-86.1%	$1.1M+337.2%	$258K-49.6%	$512K-85.5%	$3.5M+119.5%	$1.6M+671.8%	$209K+145.9%	$85K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$51.1M-10.7%	$57.2M+7.7%	$53.1M+7.5%	$49.4M-1.4%	$50.1M+5.9%	$47.4M-21.7%	$60.5M+16.3%	$52.0M
Current Liabilities	$12.0M-0.6%	$12.1M+57.6%	$7.7M+15.2%	$6.7M-31.3%	$9.7M+33.1%	$7.3M-20.0%	$9.1M+26.3%	$7.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$10.7M+66.0%	-$31.5M-242.1%	-$9.2M-937.5%	$1.1M-89.3%	$10.2M+183.2%	-$12.3M-226.4%	$9.7M-57.2%	$22.7M
Retained Earnings	-$405.1M-1.1%	-$400.8M-6.1%	-$377.8M-3.0%	-$367.0M-2.7%	-$357.2M-1.9%	-$350.5M-10.6%	-$317.0M-4.4%	-$303.5M

IMDX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$22.2M-7.2%	-$20.7M+11.3%	-$23.3M+48.8%	-$45.6M-26.8%	-$35.9M-38.3%	-$26.0M
Capital Expenditures	$3.2M+517.2%	$516K+83.6%	$281K-93.5%	$4.3M+93.1%	$2.2M+83.1%	$1.2M
Free Cash Flow	-$25.4M-19.6%	-$21.2M+10.2%	-$23.6M+52.7%	-$49.9M-30.7%	-$38.2M-40.4%	-$27.2M
Investing Cash Flow	-$3.2M-522.1%	-$512K+45.1%	-$932K+78.5%	-$4.3M+68.9%	-$14.0M-18.8%	-$11.7M
Financing Cash Flow	$28.1M+37.4%	$20.4M+67.6%	$12.2M-66.0%	$35.8M-54.3%	$78.4M+243.7%	$22.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$7.6M-37.8%	-$5.5M-23.2%	-$4.5M+28.5%	-$6.3M-7.9%	-$5.8M-9.1%	-$5.4M+3.2%	-$5.5M+7.5%	-$6.0M
Capital Expenditures	$613K-58.6%	$1.5M+40.9%	$1.1M+200.9%	$349K+13.7%	$307K+43.5%	$214K+146.0%	$87K-54.5%	$191K
Free Cash Flow	-$8.3M-17.5%	-$7.0M-26.5%	-$5.6M+16.5%	-$6.6M-8.2%	-$6.1M-10.4%	-$5.6M+0.9%	-$5.6M+8.9%	-$6.2M
Investing Cash Flow	-$613K+58.6%	-$1.5M-40.9%	-$1.1M-200.9%	-$349K-13.7%	-$307K-46.2%	-$210K-141.4%	-$87K+54.5%	-$191K
Financing Cash Flow	$24.7M+9900.8%	-$252K-110.0%	-$120K-5.3%	-$114K-100.4%	$28.6M+163.5%	$10.8M+4349.8%	-$255K-102.6%	$9.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMDX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	56.7%+17.3pp	39.3%+11.9pp	27.5%+19.3pp	8.1%-56.5pp	64.6%+117.2pp	-52.5%
Operating Margin	-1260.8%+1984.4pp	-3245.1%-1572.8pp	-1672.4%+206.2pp	-1878.6%+565.7pp	-2444.3%-0.9pp	-2443.3%
Net Margin	-1.2%+2.0pp	-3.2%-1.4pp	-1.8%+7608.0pp	-7609.8%-4693.7pp	-2916.2%-454.6pp	-2461.5%
Return on Equity	N/A	N/A	-0.1%+212.5pp	-212.6%-114.3pp	-98.3%-8.9pp	-89.4%
Return on Assets	-0.2%-0.0pp	-0.2%-0.1pp	-0.0%+72.8pp	-72.8%-32.7pp	-40.2%+13.8pp	-54.0%
Current Ratio	1.27-0.3	1.62+0.1	1.49-0.6	2.11-0.7	2.77+1.7	1.03
Debt-to-Equity	-1.82+2.0	-3.86-6.3	2.41+0.6	1.76+0.3	1.45+0.8	0.66
FCF Margin	-625.6%+501.7pp	-1127.3%+443.3pp	-1570.6%+3639.0pp	-5209.6%-3472.2pp	-1737.4%+500.0pp	-2237.4%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	46.9%+4.4pp	42.5%-11.0pp	53.5%-14.1pp	67.6%+5.6pp	62.0%+21.9pp	40.0%-3.4pp	43.5%-4.6pp	48.1%
Operating Margin	-13790.6%-11733.1pp	-2057.5%+2191.7pp	-4249.2%-2349.2pp	-1900.0%-1582.0pp	-318.0%+1944.9pp	-2262.9%+9489.3pp	-11752.2%-7298.3pp	-4453.9%
Net Margin	-13406.3%-15795.8pp	2389.5%+6564.2pp	-4174.6%-2293.9pp	-1880.7%-1568.7pp	-312.0%-2135.1pp	1823.1%+13556.1pp	-11733.0%-7377.3pp	-4355.8%
Return on Equity	N/A	N/A	N/A	-887.3%-822.0pp	-65.3%	N/A	-138.9%-119.0pp	-20.0%
Return on Assets	-10.6%-116.3pp	105.7%+130.4pp	-24.7%-5.4pp	-19.3%-8.2pp	-11.1%-88.3pp	77.2%+96.5pp	-19.2%-13.2pp	-6.1%
Current Ratio	2.54+1.3	1.27-1.5	2.79-1.2	4.04+0.3	3.75+2.1	1.62+1.1	0.53-0.9	1.38
Debt-to-Equity	-4.78-3.0	-1.82+4.0	-5.78-50.8	45.01+40.1	4.91+8.8	-3.86-10.1	6.23+3.9	2.29
FCF Margin	-25787.5%-25170.8pp	-616.7%+1518.7pp	-2135.4%-852.2pp	-1283.2%-995.7pp	-287.5%+87.0pp	-374.5%+4509.9pp	-4884.3%+1047.4pp	-5931.7%

Note: Shareholder equity is negative (-$31.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Burning Rock Biotech Ltd BNR

$106.2M

$120.2M

$354.1M

$205.1M

$21.4M

Frequently Asked Questions

What is Insight Molecular Diagnostics Inc.'s annual revenue?

Insight Molecular Diagnostics Inc. (IMDX) reported $4.1M in total revenue for fiscal year 2025. This represents a 115.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Insight Molecular Diagnostics Inc.'s revenue growing?

Insight Molecular Diagnostics Inc. (IMDX) revenue grew by 115.6% year-over-year, from $1.9M to $4.1M in fiscal year 2025.

Is Insight Molecular Diagnostics Inc. profitable?

No, Insight Molecular Diagnostics Inc. (IMDX) reported a net income of -$50K in fiscal year 2025, with a net profit margin of -1.2%.

What is Insight Molecular Diagnostics Inc.'s EBITDA?

Insight Molecular Diagnostics Inc. (IMDX) had EBITDA of -$48.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Insight Molecular Diagnostics Inc.'s gross margin?

Insight Molecular Diagnostics Inc. (IMDX) had a gross margin of 56.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Insight Molecular Diagnostics Inc.'s operating margin?

Insight Molecular Diagnostics Inc. (IMDX) had an operating margin of -1260.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Insight Molecular Diagnostics Inc.'s net profit margin?

Insight Molecular Diagnostics Inc. (IMDX) had a net profit margin of -1.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Insight Molecular Diagnostics Inc.'s free cash flow?

Insight Molecular Diagnostics Inc. (IMDX) generated -$25.4M in free cash flow during fiscal year 2025. This represents a -19.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Insight Molecular Diagnostics Inc.'s operating cash flow?

Insight Molecular Diagnostics Inc. (IMDX) generated -$22.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Insight Molecular Diagnostics Inc.'s total assets?

Insight Molecular Diagnostics Inc. (IMDX) had $25.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Insight Molecular Diagnostics Inc.'s capital expenditures?

Insight Molecular Diagnostics Inc. (IMDX) invested $3.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Insight Molecular Diagnostics Inc. spend on research and development?

Insight Molecular Diagnostics Inc. (IMDX) invested $15.9M in research and development during fiscal year 2025.

How many shares does Insight Molecular Diagnostics Inc. have outstanding?

Insight Molecular Diagnostics Inc. (IMDX) had 29M shares outstanding as of fiscal year 2025.

What is Insight Molecular Diagnostics Inc.'s current ratio?

Insight Molecular Diagnostics Inc. (IMDX) had a current ratio of 1.27 as of fiscal year 2025, which is considered adequate.

What is Insight Molecular Diagnostics Inc.'s debt-to-equity ratio?

Insight Molecular Diagnostics Inc. (IMDX) had a debt-to-equity ratio of -1.82 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Insight Molecular Diagnostics Inc.'s return on assets (ROA)?

Insight Molecular Diagnostics Inc. (IMDX) had a return on assets of -0.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Insight Molecular Diagnostics Inc.'s cash runway?

Based on fiscal year 2025 data, Insight Molecular Diagnostics Inc. (IMDX) had $11.6M in cash against an annual operating cash burn of $22.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Insight Molecular Diagnostics Inc.'s debt-to-equity ratio negative or unusual?

Insight Molecular Diagnostics Inc. (IMDX) has negative shareholder equity of -$31.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Insight Molecular Diagnostics Inc.'s Altman Z-Score?

Insight Molecular Diagnostics Inc. (IMDX) has an Altman Z-Score of -26.39, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Insight Molecular Diagnostics Inc.'s Piotroski F-Score?

Insight Molecular Diagnostics Inc. (IMDX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Insight Molecular Diagnostics Inc.'s earnings high quality?

Insight Molecular Diagnostics Inc. (IMDX) has an earnings quality ratio of 441.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Insight Molecular Diagnostics Inc. cover its interest payments?

Insight Molecular Diagnostics Inc. (IMDX) has an interest coverage ratio of -469.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Insight Molecular Diagnostics Inc.?

Insight Molecular Diagnostics Inc. (IMDX) scores 47 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.